SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trinity Biotech (TRIBY)
TRIB 0.881-2.2%Jan 29 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joel W. Hunt who wrote (8480)3/10/1998 5:54:00 PM
From: Scott H. Davis  Read Replies (1) of 14328
 
Undervalued, probably, but many times, don't think so, at least from a value perspective. Look at the ratios for TRIBY vs EQNX, PERLF, EMLX, PTIX and compare projected growth rates (remember that while Zacks shows .15 estimated for this year, Brendan stated that he was uncomfortable with that, and suggested thinking about a 30% growth rate.

So TRIBY is well positioned, has a good foundation and plan, a favorable development/tax environment. Lot of growth potential, without a lot of downside risk based on today's prices.

I just can't agree with claims it should be worth many time more.
Sure we can all point to much more richly valued stocks. TRIBY comes to mind in May 96.

So if we can set our expectation level based on the realities of today
(price & realistic growth rate), holding TRIBY can be much less frustrating.

How many other investments can you identify that offer a realistic prospect of a 30% return without real high risk? IMSCO, Scott
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext